Dublin, Aug. 12, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Asthma: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis" report to their offering.

The increasing availability of biologics will drive growth in the asthma market during 2015-24, but prescribing will be restricted to patients with severe persistent uncontrolled asthma.

This report addresses the following questions:

- Where will the newly approved Nucala and Cinqair be positioned in the treatment algorithm and will they directly compete with Xolair?
- What are pulmonologists' views on the late-phase interleukin (IL) inhibitors and how will they differentiate between them?
- What clinical endpoints do pulmonologists want to see in trial programs of biologics?
- How will the loss of brand exclusivity impact leading inhaled corticosteroid/long-acting beta 2 agonist (ICS/LABA) inhalers?

Key Topics Covered:

FORECAST: ASTHMA IN THE US, JAPAN, AND 5EU

- Advair (fluticasone/salmeterol)
- benralizumab
- Breo (fluticasone furoate/vilanterol)
- Cinqair (reslizumab)
- Dulera (mometasone/formoterol)
- Flutiform (fluticasone/formoterol)
- Nucala (mepolizumab)
- Singulair (montelukast)
- Spiriva (tiotropium)
- Symbicort (budesonide/formoterol)
- Xolair (omalizumab)
- Primary Research Methodology

TREATMENT: ASTHMA

- Primary Research Methodology
- Disease Definition and Diagnosis
- Patient Segmentation
- Country Treatment Trees
- Current Treatment Options
- Prescribing Trends
- Impact of Generics
- Unmet Needs in Asthma

EPIDEMIOLOGY: ASTHMA

- Disease Background
- Sources and Methodology
- Forecast
- Epidemiologist Insight
- Strengths and Limitations

MARKETED DRUGS: ASTHMA

- Product profile: Advair
- Product profile: Asmanex
- Product profile: Breo
- Product profile: Cinqair
- Product profile: Dulera
- Product profile: Flovent
- Product profile: Flutiform
- Product profile: Nucala
- Product profile: Pulmicort
- Product profile: Singulair
- Product profile: Spiriva
- Product profile: Symbicort
- Product profile: Xolair

PIPELINE: ASTHMA

- Clinical Pipeline Overview
- Early-Phase Opportunities
- Comparator Therapy
- Clinical Trial Design
- Product profile (late stage): QVM1
- Product profile (late stage): benralizumab
- Product profile (late stage): dupilumab
- Product profile (late stage): lebrikizumab
- Product profile (late stage): masitinib
- Product profile (late stage): tralokinumab

For more information about this report visit http://www.researchandmarkets.com/research/d85tsd/asthma

Related Topics: Asthma Drugs

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         press@researchandmarkets.com

         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900

         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.